TRINETRA › Sectors › Healthcare
Biocon Limited (BIOCON) — share price, P/E and fundamentals
Biocon Limited (NSE: BIOCON) closed at ₹351.80 on 30 Oct 2026, -1.2% over one year, against a 52-week range of ₹321.30 – ₹447.15.
In the quarter ended 30 Jun 2026 (consolidated, filed 5 Aug 2026) it reported revenue of ₹4,336 cr and net profit of ₹141 cr, a 3.3% net margin; revenue grew 10.0% and profit grew 31.7% year on year.
On four consecutive filed quarters its trailing P/E is 115.8; since 8 May 2025 its own P/E has ranged from 52.6 to 181.3 (median 64.0), and today's reading is higher than 71% of those 366 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 1.7%, ROCE 2.8%, debt-to-equity 0.44, Piotroski F-score 6 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 10% of 63 sector peers; PBT margin higher than 5% of 63 sector peers; ROE higher than 8% of 63 sector peers.
Key figures
| Last close | ₹351.80 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -9.1% / +0.6% / -1.2% |
| 52-week low – high | ₹321.30 – ₹447.15 |
| Market capitalisation | ₹57,329 cr |
| Trailing P/E | 115.8 |
| Price / book | 1.68 |
| EV / EBITDA | 20.2 |
| Earnings yield | 0.9% |
| TTM EPS | ₹3.04 |
| TTM net profit | ₹495 cr |
| Quarter revenue | ₹4,336 cr |
| Quarter net profit | ₹141 cr |
| Net margin | 3.3% |
| Revenue growth (YoY) | +10.0% |
| Profit growth (YoY) | +31.7% |
| Return on equity | 1.7% |
| ROCE | 2.8% |
| Debt / equity | 0.44 |
| Current ratio | 1.22 |
| Free cash flow | ₹196 cr |
| Piotroski F-score | 6 / 9 |
| Average daily turnover (50 days) | ₹95.5 cr |
Against Healthcare peers
| Metric | BIOCON | Peer median | Percentile |
|---|---|---|---|
| Net margin | 3.25 | 12.89 | 10 |
| PBT margin | 2.94 | 17.68 | 5 |
| ROE | 1.66 | 13.87 | 8 |
| ROCE | 2.75 | 17.26 | 5 |
| Debt / equity | 0.44 | 0.11 | 86 |
| Cash conversion | 5.41 | 1.25 | 98 |
| Trailing P/E | 115.75 | 43.07 | 95 |
| P/B | 1.68 | 6.02 | 2 |
Questions
What is the P/E ratio of Biocon Limited?
Biocon Limited's trailing P/E is 115.8, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 8 May 2025 its P/E has ranged 52.6–181.3.
What were Biocon Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Biocon Limited reported revenue of ₹4,336 cr and net profit of ₹141 cr (consolidated), filed with the exchange on 5 Aug 2026.
What is Biocon Limited's ROE?
Return on equity is 1.7% based on the balance sheet dated 31 Mar 2026.
Does Biocon Limited have debt?
Debt-to-equity is 0.44 on the balance sheet dated 31 Mar 2026.
What is BIOCON's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, BIOCON traded between ₹321.30 and ₹447.15.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.